HPC › Bio › Glossary
Oestrogen is a family of steroid hormones synthesised primarily in the ovaries, adrenal cortex, and adipose tissue. Three biologically active forms exist: oestradiol (E2), which dominates during reproductive years; oestrone (E1), which predominates after menopause; and oestriol (E3), which rises during pregnancy. All three act via nuclear receptors to regulate reproduction, bone maintenance, cardiovascular function, and cognition.
Oestrogen is produced in varying proportions across the lifespan: reproductive-age women rely primarily on oestradiol, postmenopausal women on oestrone, and pregnant women on oestriol.
How it works
Oestrogens are synthesised from androgens via the enzyme aromatase. In premenopausal women, aromatase in ovarian granulosa cells converts androstenedione and testosterone into oestradiol and oestrone. After menopause, ovarian production falls sharply, and adipose-derived aromatisation becomes the dominant source 1. In men and children, peripheral tissues including adipose and adrenal cortex also produce small quantities of oestrogen through the same pathway.
Receptor binding determines biological action. On binding oestradiol, oestrogen receptors ERalpha and ERbeta dissociate from protective heat-shock protein complexes, translocate into the nucleus, and bind oestrogen response elements on target genes to alter transcription 1. Oestradiol is approximately 10-fold more potent than oestrone and 100-fold more potent than oestriol at these receptors 1. A second, faster signalling pathway operates at the cell membrane via the G-protein-coupled receptor GPER1, producing rapid physiological responses independent of gene transcription.
In bone, oestrogen suppresses resorption by inducing programmed cell death in osteoclasts and downregulating RANKL, the signalling protein that drives osteoclast formation 2. This protective effect explains why oestrogen withdrawal at menopause triggers accelerated bone loss rather than merely ending a positive process. Beyond the skeleton, oestrogen receptors are expressed in the cardiovascular system, central nervous system, and liver, accounting for its broad systemic influence.
Example
A woman in her early fifties notices a marked increase in joint discomfort and disrupted sleep alongside vasomotor symptoms such as hot flushes. Blood work confirms she is in the early postmenopausal phase, with oestradiol levels well below reproductive-age norms. Her clinician discusses hormone therapy, weighing her personal cardiovascular and bone fracture risk against the documented relief oestrogen replacement provides for vasomotor and genitourinary symptoms.
Oestrogen decline is not a single-symptom event; it is a systemic transition with simultaneous implications for bone integrity, cognition, and cardiovascular risk.
Why it matters
The practical significance of oestrogen is clearest at menopause, when its decline drives accelerated bone loss, vasomotor symptoms, and, in some women, cognitive vulnerability 4. The 2002 Women's Health Initiative provided the most consequential evidence on hormone therapy: combined oestrogen-plus-progestin therapy reduced hip fractures and colorectal cancers but increased absolute risk of coronary heart disease by 7 events and breast cancer by 8 events per 10,000 person-years 3. Oestrogen-only therapy carries a different risk profile, and formulation matters.
Timing also determines cognitive outcomes. A 2024 systematic review found that oestrogen therapy initiated at or near menopause onset improves global cognition and verbal memory, whereas later initiation confers no measurable cognitive benefit 4. This 'critical window' has real implications: a woman who delays the conversation may miss the period during which oestrogen supports neural health. Memory, sleep quality, bone integrity, and cardiovascular risk are not independent variables but an integrated system reflecting hormonal status.
What are the three forms of oestrogen and what does each do?+
The three biologically active forms are oestradiol (E2), oestrone (E1), and oestriol (E3). Oestradiol dominates during reproductive years and carries the strongest receptor-binding activity, roughly 10-fold greater than oestrone. Oestrone predominates after menopause. Oestriol rises markedly during pregnancy and is the weakest of the three {{cite:10.1016/bs.apcsb.2019.01.001}}.
Does oestrogen protect the brain and memory?+
A 'critical window' effect is supported by a 2024 systematic review: oestrogen therapy begun at or near menopause onset improves global cognition and verbal memory, while initiation several years later offers no measurable cognitive benefit {{cite:10.3389/fendo.2024.1350318}}. The neuroprotective mechanism likely involves oestrogen receptor signalling in hippocampal and prefrontal circuits.
Is oestrogen therapy safe after menopause?+
Safety depends on formulation, timing, and individual risk profile. The Women's Health Initiative found that combined oestrogen-plus-progestin therapy increased absolute coronary heart disease risk by 7 events and breast cancer risk by 8 events per 10,000 person-years, while reducing hip fractures and colorectal cancer {{cite:10.1001/jama.288.3.321}}. Oestrogen-only therapy has a different risk profile.
How does oestrogen affect bone density and osteoporosis risk?+
Oestrogen suppresses bone resorption by inducing osteoclast cell death and downregulating RANKL, which drives osteoclast formation {{cite:10.1152/physrev.00033.2015}}. When oestrogen falls at menopause, osteoclast activity rises sharply, producing bone loss of up to 3% per year in the first five postmenopausal years. This rapid loss underpins the majority of osteoporotic fractures in women.
